Deepti Venkatraman
Overview
Explore the profile of Deepti Venkatraman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
3.
Ricciuti B, Lamberti G, Puchala S, Mahadevan N, Lin J, Alessi J, et al.
J Clin Oncol
. 2024 Jan;
42(11):1311-1321.
PMID: 38207230
Purpose: Although immune checkpoint inhibitors (ICI) have extended survival in patients with non-small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently develops after an initial benefit. However, the mechanisms...
4.
Alessi J, Wang X, Elkrief A, Ricciuti B, Li Y, Gupta H, et al.
J Thorac Oncol
. 2023 May;
18(11):1524-1537.
PMID: 37247843
Introduction: Although gene-level copy number alterations have been studied as a potential biomarker of immunotherapy efficacy in NSCLC, the impact of aneuploidy burden and chromosomal arm-level events on immune checkpoint...
5.
Alessi J, Elkrief A, Ricciuti B, Wang X, Cortellini A, Vaz V, et al.
J Thorac Oncol
. 2023 Feb;
18(6):731-743.
PMID: 36775193
Introduction: Although programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay of first-line treatment for advanced NSCLC, factors associated...
6.
Ricciuti B, Arbour K, Lin J, Vajdi A, Vokes N, Hong L, et al.
J Thorac Oncol
. 2021 Nov;
17(3):399-410.
PMID: 34740862
Introduction: STK11 and KEAP1 mutations (STK11 mutant [STK11] and KEAP1) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been associated with resistance to programmed...
7.
Ricciuti B, Naqash A, Naidoo J, Sehgal K, Miller A, Kehl K, et al.
JTO Clin Res Rep
. 2021 Sep;
1(4):100074.
PMID: 34589955
Introduction: The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and NSCLC. Whether this association exists...
8.
Ricciuti B, Recondo G, Spurr L, Li Y, Lamberti G, Venkatraman D, et al.
Clin Cancer Res
. 2020 Apr;
26(15):4135-4142.
PMID: 32332016
Purpose: DNA damage response and repair (DDR) gene alterations are associated with increased tumor-infiltrating lymphocytes, higher genomic instability, and higher tumor mutational burden (TMB) in cancer. Whether DDR alterations are...
9.
Recondo G, Bahcall M, Spurr L, Che J, Ricciuti B, Leonardi G, et al.
Clin Cancer Res
. 2020 Feb;
26(11):2615-2625.
PMID: 32034073
Purpose: Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II...
10.
Balaji A, Zhang J, Wills B, Marrone K, Elmariah H, Yarchoan M, et al.
J Oncol Pract
. 2019 Aug;
15(9):e825-e834.
PMID: 31386608
Purpose: Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs). The proportion of patients who are hospitalized for irAEs and their spectrum, management, and outcomes are not well described. Methods:...